Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
77 hedge funds and large institutions have $328M invested in Chinook Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 17 closing their positions.
249% more capital invested
Capital invested by funds: $93.9M → $328M (+$234M)
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
10% more funds holding
Funds holding: 70 → 77 (+7)
55% less call options, than puts
Call options by funds: $493K | Put options by funds: $1.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ALSV
ATP Life Science Ventures
New York
|
+$60.8M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$47.8M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.9M |
| 4 |
O
OrbiMed
New York
|
+$18.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.5M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.38M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.16M |
| 4 |
Renaissance Technologies
New York
|
-$614K |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$330K |
KDNY Hedge Fund Activity: Q4 2020 in Review
77 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2020, worth a combined $328M — up 249% from $93.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KDNY positions and 17 closed out — a net gain of 8 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was ATP Life Science Ventures, opening a new position worth an estimated $60.8M. The largest seller was Acadian Asset Management, cutting an estimated $1.5M.
- 77 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2020, up from 70 in Q3 2020.
- Funds reported $328M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2020, up 249% quarter-over-quarter.
- 25 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2020 and 17 closed out, a net change of +8 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2020 was ATP Life Science Ventures, an estimated $60.8M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2020 was Acadian Asset Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q4 2020.